Harvard Title
Assistant Professor of Neurology
Other Affiliations
Brigham and Women's Hospital
Harvard Vanguard Medical Associates
Address
Harvard Vanguard Medical Associates
111 Grossman Dr
Braintree MA 02184
Publications View
Preliminary results of a randomized placebo-controlled double-blind trial of weekly docetaxel combined with imatinib in men with metastatic androgen-independent prostate cancer (AIPC) and bone metastases (BM).
Authors: Mathew P, Thall PF, Johnson MM, Oh WK, Meluch AA, Morris MJ, Troncoso P, Bucana CD, Fidler IJ, Logothetis CJ.
J Clin Oncol
View full abstract on Pubmed
J Clin Oncol
View full abstract on Pubmed
Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate cancer previously treated with taxanes.
Authors: Rodney A, Dieringer P, Mathew P, Jonasch E, Tannir N, Pagliaro LC.
Cancer
View full abstract on Pubmed
Cancer
View full abstract on Pubmed
Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer.
Authors: Mathew P, Thall PF, Jones D, Perez C, Bucana C, Troncoso P, Kim SJ, Fidler IJ, Logothetis C.
J Clin Oncol
View full abstract on Pubmed
J Clin Oncol
View full abstract on Pubmed
Combination docetaxel and platelet-derived growth factor receptor inhibition with imatinib mesylate in prostate cancer.